Structure Therapeutics is a ‘no-brainer takeout’ target, says Mizuho’s Jared Holz

June 3, 2024
Structure Therapeutics is a ‘no-brainer takeout’ target, says Mizuho’s Jared HolzStructure Therapeutics is a ‘no-brainer takeout’ target, says Mizuho’s Jared Holz

Jared Holz, Mizuho, joins ‘Fast Money’ to talk Structure Therapeutics soaring on its GLP-1 data and M&A targets in the obesity drug space.


 

Share This

Latest Mizuho News

Prefer Novo short-term as a GLP-1 play, says Mizuho’s Jared Holz

Prefer Novo short-term as a GLP-1 play, says Mizuho’s Jared Holz

April 20, 2026
Iran war highlights risks in the chemical supply chain

Iran war highlights risks in the chemical supply chain

April 15, 2026
Wall Street jumps to near one-month highs after US-Iran ceasefire

Wall Street jumps to near one-month highs after US-Iran ceasefire

April 8, 2026

Mizuho news from around the globe

back-to-top-blue